Effector definition
Examples of Effector in a sentence
The Parties will conduct a research and development collaboration to discover, identify, characterize and optimize Tether and Effector combinations to create Compounds for further Development in the Primary Indication or Non-Primary Indications in the Field pursuant to the Research Plan (the “Research Program”).
To further the discussions, Pandion agrees, from the Effective Date until the [**] of the Effective Date, to notify Astellas in writing prior to negotiating a term sheet with a Third Party regarding a potential collaboration, outlicense, sale or similar partnership involving any bispecific antibody or other biologic consisting of an Effector and any tissue-tethering proteins not designated as Tether Targets under this Agreement.
Notwithstanding the foregoing, the license granted under this Section 7.1(b) shall be non-exclusive with respect to Pandion Effector Technology, including any Effectors included in a Licensed Compound.
Purchaser shall give prompt notice to the Company of any breach by Purchaser or Acquisition Sub, either individually or in the aggregate with other breaches, of (i) any representation or warranty of Purchaser or Acquisition Sub contained in Article V of this Agreement which has had or could reasonably be expected to have a Company Material Adverse Effector, or (ii) any covenant, condition, or agreement to be complied with or satisfied by Purchaser hereunder.
For clarity, such license does not include any right to manufacture, sell, supply, use or import any products which contain GNE’s CD3 Effector (including anti-CD3 antibodies, antigen-binding fragments thereof and other derivatives and variants) and also such license does not obligate GNE to provide any material or technology transfer to Immunocore or any Third Party.
Under the terms of the agreement, Daiichi Sankyo will acquire a license to Zymeworks’ Azymetric™ and Effector Function Enhancement and Control Technology (EFECT™) platforms to develop a bi-specific antibody therapeutic, for which Zymeworks will receive an upfront technology access fee and research support.
Again by way of non-limiting example, CONKWEST agrees that it shall not work with any Third Party on any TTM-modified Effector Cell Line-based therapy.
If CONKWEST desires to use CD16 expressing NK-92 cell lines as an Effector Cell Line or otherwise in connection with TTM, then CONKWEST must do so under the terms and conditions of this Agreement and the CD16 expressing NK-92 cell lines shall be and be deemed to be included within the definition “Effector Cell Line” and subject to the exclusive rights of SRNE hereunder.
By way of non-limiting example, SRNE agrees that any monoclonal antibody used to develop a Project CAR shall be used exclusively for that Project and shall not be the subject of any relationship with a Third Party in any TTM-modified Effector Cell Line-based therapy, excluding the purified recombinant antibody or antibody drug conjugates (ADC) format of the monoclonal antibody.
The Parties hereby agree to exclusively collaborate in the Program for the purpose of jointly developing any and all TTM-modified Effector Cell Lines.